Market Place
Sourcing Support
All News #Library
Biotech
Aclaris Reports Positive Phase 1a Data for ATI-052 Antibody
28 Apr 2026 //
GLOBENEWSWIRE
Provide Additional Support for Therapeutic Potential of ATI-2138
27 Mar 2026 //
GLOBENEWSWIRE
Aclaris Therapeutics Presents ATI-2138 Phase 2A Trial Results
20 Mar 2026 //
GLOBENEWSWIRE
Aclaris Completes Bosakitug Phase 2 AD Enrollment
18 Mar 2026 //
GLOBENEWSWIRE
Aclaris Pharma Starts Asthma Trial With Bispecific Antibody
24 Feb 2026 //
GLOBENEWSWIRE
Aclaris ITK/JAK3 Inhibitor Shows Hair Regrowth in Alopecia Model
27 Jan 2026 //
GLOBENEWSWIRE
Aclaris Starts ATI-052 Phase 1b POC Trial in Atopic Dermatitis
12 Jan 2026 //
GLOBENEWSWIRE
Aclaris Therapeutics Reports Positive Phase 1A Results
06 Jan 2026 //
GLOBENEWSWIRE
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index
19 Dec 2025 //
GLOBENEWSWIRE
Aclaris Therapeutics Joins Three November Healthcare Conferences
29 Oct 2025 //
GLOBENEWSWIRE
Aclaris Therapeutics` ATI-2138 Achieves Goals in Ph 2a Trial
29 Jul 2025 //
GLOBENEWSWIRE
Aclaris Therapeutics Starts Phase 1a/1b for Bispecific Antibody
23 Jun 2025 //
GLOBENEWSWIRE
Aclaris Starts Ph2 Trial Of Bosakitug In Atopic Dermatitis
02 Jun 2025 //
GLOBENEWSWIRE
Aclaris Therapeutics Gets FDA IND Clearance for ATI-052 Antibody
22 Apr 2025 //
GLOBENEWSWIRE
Aclaris Therapeutics Announces Global License Agreement with Biosion
18 Nov 2024 //
GLOBENEWSWIRE
Biosion Announces Global License with Aclaris for Immunology Assets
18 Nov 2024 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.